Abstract: An acupressure walking machine for applying pressure to foot reflex zones is disclosed. The present invention relates to an acupressure walking machine for applying pressure to foot reflex zones, the walking machine additionally providing an embossing belt, which is made from an elastic material and circulating in a caterpillar form, to the lower side of a running belt circulating in a caterpillar form so as to restrain acupressure stones from rapidly gathering at a curved turning section, such that the uniform dispersion of the acupressure stones is induced, thereby uniformly distributing the acupressure stones placed on the running belt.

Abstract: Embodiments of work stations for use in medical dose preparation management system. A work station may include a camera stand. The camera stand may include a housing enclosing a camera and one or more light sources therein. As such, the camera and light sources may be directed at a medical dose preparation staging region to capture medical dose preparation images of the medical dose preparation staging region. The camera stand may include an adjustable support positionable in a plurality of positions to dispose the camera and light source relative to the medical dose preparation staging region. A base with a removable tray may be provided that include medical receptacle engagement features. The work stations may facilitate improved image quality, efficiency of work flows carried out at the work station, and administrative tasks such as cleaning.

Abstract: A system for administering tablets, capsules, caplets, nutritional supplements, pills, and the like includes a vessel having a container and cap, with intermediate closure assembly selectively permitting passage of a liquid coating (oil) therebetween. Pills between the closure (valve) and cap are coated by tilting the closed vessel while the cap is sealed on the container. When the vessel is upright, the coating liquid drains back into the container. Removal of the cap closes (seals) the closure assembly against escape of liquid from the container. A user may then pour a pill or pills from the basket directly into the mouth without touching fingers to the coating thereon. Oils and water-based liquids in the mouth and esophagus repel, so pills slide down, making swallowing easier.

Abstract: A device for separating broken fragments of particles from the particles, comprising a floor arranged such that it receives the particles and the broken fragments, connected to a vibration device arranged such that it makes the floor undergo a vibratory movement, the floor being pierced with orifices to allow the broken fragments to pass through the orifices without allowing the particles to pass therethrough, and a ceiling arranged substantially parallel to the floor. The device further comprises an actuator arranged so as to move the ceiling between a first position in which it is located at a distance from the floor and a second position in which it is in contact with the floor such that the broken particle fragments stuck in the orifices are expelled therefrom.

Abstract: A system for medication delivery comprises a Package containing a medication and a Dosing mechanism for delivering a dose of a drug, formulated as multiparticulate, microspheres, powder or liquid. The Package comprises a bottle, a bottle insert that covers the bottle opening and includes a dispense nozzle. The dispense nozzle is sealed using a valve that opens when the Dosing device is engaged with the bottle. A closure covers the bottle insert and closes the bottle. The Dosing device, similar to an oral syringe, comprises a barrel with a valve at its distal end, a plunger and a dose control clip for attachment to the plunger. After the dosing device is connected to the bottle valve, withdrawal of the plunger causes the dosing device to receive a dose of drug, the user pushes the plunger which pushes the MP drug through the valve and into a patient's mouth.

Abstract: Disclosed herein are modular container systems having child-resistant containers, tray inserts and tray frames. Also disclosed are methods using the modular container systems and methods of storing substances in containers. The containers have a container base and a container cap and provide for child-resistant containers. A user can releasably remove the container cap from container base with a squeeze and lift sequence. For example, the user squeezes opposite sides of the container base, which releases a locking mechanism and allows for removal of the cap by lifting or pulling the container cap off from the container base. The components of the modular container system are modular and stackable. The modular system allow for organized, efficient, accessible and storage of the child-resistant containers. The modular container system also allows for easy counting, sorting and processing of the containers.

Abstract: A holder system comprises a holder (1), provided with a seal (2) and an external circumferential band (3). A slip ring (4) is provided which can be pressed against the seal (2) in the direction shown by the arrows (5) provided on the slip ring to form a snap fit with the holder. Above the holder is a collar (6) designed to engage with the upper surface (7) of the holder. FIG. 2 shows a teat (8) provided with a band (9) at its lower end which engages with a lug inside the holder (1) to provide a tight seal, the cap (10) is placeable in the collar. The attachment of the collar (6) to the holder (1) secures the teat in position.

Abstract: Polymerizable dental compositions comprising a redox initiator system is disclosed. The redox initiator system comprises a photolabile transition metal complex that photolyzes and initiates the redox cycle.

Abstract: Polymerizable compositions comprising a redox initiator system is disclosed. The redox initiator system comprises a photolabile transition metal complex that photolyzes and initiates the redox cycle. Dental compositions comprising dental resins and the photolabile redox initiator system are also described.

Abstract: A method for repairing dentition, including milling beta tricalcium phosphate with sufficiently high energy to substantially distressed its lattice structure, mechanochemically chelating an edible acid thereto to yield functionalized calcium phosphate moieties, and incorporating the functionalized calcium phosphate moieties into an edible material to yield a calcium phosphate delivery system. The calcium phosphate delivery system is introduced into an oral environment and dentition is repaired. The functionalized calcium phosphate moiety is characterized by weakly bonded fumaric acid at least partially wrapped around distressed calcium phosphate particles, and dentition repair occurs at a dentition depth of at least 10 microns below the surface.

Abstract: Individually packaged topical formulations comprising about 0.25 to about 6% w/w of glycopyrrolate for the treatment of hyperhidrosis, wherein said wipe is contained within a pouch resistant to leakage. The formulations may further comprise ethanol, a buffering agent and water. In addition, the formulations may further comprise a polymer system comprising a hydrophobic polymer in combination with a hydrophilic polymer.

Abstract: An aqueous personal care composition comprising 0.5 to 10 wt % polymer encapsulated particles of titanium dioxide or zinc oxide; said polymer encapsulated particles comprising: (i) particles of titanium dioxide or zinc oxide having an average particle diameter from 10 to 200 nm; (ii) 0.25 to 10 wt % water-soluble sulfur acid-functional first polymer, based on weight of said particles of titanium dioxide or zinc oxide; and (iii) from 10% to 200%, by weight second polymer, based on weight of said particles of titanium dioxide or zinc oxide, wherein the second polymer at least partially encapsulates said particle of titanium dioxide or zinc oxide.

Abstract: An object of the present invention is to provide a composition providing like a skin care cosmetics appearance and a texture, and being capable of correcting irregularities such as pores without using an inorganic powder having a high covering power. A composition, comprising: an aqueous medium; a lipophilic porous powder dispersed in the aqueous medium; an oil having a viscosity of 100 mPa·s or less, the oil being kept by at least some of pores of the lipophilic porous powder; and a dispersing agent for dispersing the lipophilic porous powder in the aqueous medium.

Abstract: An antiperspirant aerosol product having good sustainability characteristics and comprising an anhydrous antiperspirant aerosol composition comprising particulate antiperspirant active suspended in a carrier oil, the ratio of propellant to 5 base composition being from 2:1 to 4:1 by weight and an aerosol dispenser comprising a container body, an aerosol valve, and a valve actuator; characterised in that the particulate antiperspirant active comprises a basic aluminium chloride compound of formula Al2OH4.4Cl1.6 to Al2OH4.9Cl1.1, water soluble calcium salt and an amino acid and the aerosol valve of the aerosol 10 dispenser has a vapor phase tap (VTP) to restrictive tailpiece (RTP) ratio of from 0.6:1 to 1.2:1.

Abstract: Aspects of the present invention are directed to a method for improving the occlusiveness of a topical pharmaceutical or cosmetic formulation in use in a patient in need thereof, comprising adding to the formulation at least 0.1- to about 10% w/w of one or more of a monofatty acid ester of glycerin and/or one or more of a monofatty acid ester of glycol, or mixtures thereof. Aspects of the present invention are also directed to a method for maintaining skin barrier efficiency of the stratum corneum of a patient in need thereof, comprising applying to the skin of said patient a pharmaceutical or cosmetic formulation containing at least 3% w/w of one or more of a monofatty acid ester of glycerin and/or one or more of a monofatty acid ester of glycol, or mixtures thereof.

Abstract: The invention provides for a topical o/w emulsion having moisturizing, and protecting, repairing or restoring the skin lipid barrier of the lips of a mammal, and is a topical oil-in-water emulsion composition comprising: a discontinuous oil phase; a continuous aqueous phase comprising water; a thickening agent; at least one lamellar membrane structure comprising an alkyl amphiphilic component, an ester of a branched fatty acid and a branched fatty alcohol, a fatty acid, a fatty alcohol, and optionally a phospholipid; and wherein in use the composition has a water vapor transmission rate of less than 65 g·m?2·hr?1 measured in vitro.

Abstract: The invention relates to a composition in form of an oil-in-water emulsion comprising: a) a dispersed hydrophobic phase comprising at least one hydrophobic UV-screening agent and optionally at least one oil, said oil being selected from the group consisting of silicone oils, hydrocarbonated oils, and any mixture thereof; b) a continuous aqueous phase comprising from 0.1% to 20% by weight, relative to the total weight of the composition, of at least one C1-C4 alcohol with at least one hydroxyl group, linear or branched, saturated or unsaturated; and c) at least one hydrophobic particle selected from the group consisting of hydrophobic silicas, hydrophobic cellulose, starch, talc, silicone resin powders, hollow hemispherical silicone particles, polyamide powders, hydrophobic pigments, and any mixture thereof; d) at least one gellan gum or a derivative thereof, and e) at least one hydrophilic UV-screening agent.

Abstract: The present invention relates to cosmetic composition having an improved smearing property. The cosmetic composition according to the present invention is directed to a water-in-oil type cosmetic composition containing a film former in an external phase, the composition being characterized by further containing a thickener in an internal phase. The thickener serves to form a kind of a bridge between the skin and the film former in an external phase, of which the affinity with the skin may deteriorate. According to the present invention, the smearing of the cosmetic composition can be improved more pragmatically and effectively by a combination with an external-phase film application manner of the prior art.

Abstract: A core shell microcapsule wherein the liquid core of the microcapsule comprises solvent and climbazole dissolved in the solvent in a weight ratio of at most 8:1, preferably at most 5:1, solvent:climbazole. Also a process to manufacture the core shell microcapsule comprising the steps of: a) Dissolving climbazole in solvent to form an oil phase; b) Mixing the oil phase with an oil soluble first component of a shell forming polymerization system; c) Dispersing the mixture from step b in an aqueous phase which either contains, or has added to it, a water soluble second component of a shell forming polymerization system; d) Forming microcapsules by reaction of the first and second components of the polymerization system to encapsulate the climbazole dissolved in the solvent; and e) Optionally separating the formed microcapsules from the aqueous phase. Also a hair care composition comprising surfactant and at least 0.

Abstract: A topical skin composition and methods for its use are described. The composition can include a plurality of first plasmonic noble metal nanostructures having an aspect ratio of greater than 1 and being configured to absorb electromagnetic radiation from an artificial light source and/or from a solar radiation source to produce a first localized surface plasmon resonance (LSPR), and a plurality of second plasmonic noble metal nanostructures having an aspect ratio of greater than 1 and being configured to absorb electromagnetic radiation from a solar radiation source to produce a second LSPR.

Abstract: Disclosed is a personal care composition comprising turbostratic boron nitride, porous silica having a specific surface area of higher than 300 m2/g, and a cosmetically acceptable carrier.

Abstract: A low-water cleansing composition is provided that includes 5.0 wt. % to less than 40 wt. % of one or more C1-C8 alcohol, at least 10.0 wt. % of a mixture of two or more surfactants, at least 0.05 wt. % of a pH adjuster; and water, the concentrations being based on a total weight of the low-water cleansing composition.

Abstract: A non-antimicrobial cleansing composition is disclosed comprising from about 10.0 wt. % to less than about 40 wt. % of one or more C1-C8 alcohols; about 0.5 wt. % to about 10.0 wt. % of at least one primary surfactant; 0 wt. % to about 10.0 wt. % of at least one secondary surfactant, with the primary and secondary surfactants having an HLB value greater than 8; a pH adjusting agent; and water. The composition does not achieve a microbial kill level greater than 2.0 log.

Abstract: A hair deforming treatment agent comprising the following components (A), (B) and (C): (A) glyoxylic acid, or a hydrate or a salt thereof, (B) a compound represented by the following formula (1): wherein R1 represents H or a methyl group, A1, A2 and B each represent H, an alkyl group, an alkenyl group, etc., D represents H, OH, a methyl group, an alkoxy group, etc., and E represents H, a methyl group, an alkoxy group, etc., and (C) water.

Abstract: It is provided a combination comprising diaminopyrimidine oxide, oleanolic acid, biotinoyl tripeptide-1, apigenin, biotin, adenosine or an adenosine derivative, and Gingko biloba, a topical composition comprising a therapeutically effective amount of the combination together with appropriate topical cosmetically or pharmaceutically acceptable excipients or carriers. It is also provided the composition for use in reducing or preventing the loss of hair and/or stimulating its growth.

Abstract: The instant disclosure relates to essentially anhydrous hair-treatment compositions. The anhydrous hair-treatment compositions typically include: one or more polyurethane latex polymers; one or more bis-urea derivatives; and one or more solvents. Additional components such as silicones, auxiliary agents, etc., can also be included. The instant disclosure also relates to kits that include the essentially anhydrous hair-treatment compositions and to methods for treating hair with the essentially anhydrous hair-treatment compositions.

Abstract: The present invention relates primarily to the use of certain hydroxybenzoic acid amides or the salts or mixtures thereof for masking an unpleasant taste impression, preferably of a bitter, adstringent, dusty, dry, floury, rancid, metallic and/or cardboard taste or aftertaste, of one or more unpleasant-tasting peptides or of certain amino acid mixtures. The invention further relates to a corresponding method for masking unpleasant taste impressions and to novel preparations.

Abstract: The invention relates to a composition comprising melatonin, a metabolite or derivative thereof and coenzyme Q10 and to use thereof for the production of a pharmaceutical or cosmetic composition for the treatment of the skin, said composition potentiating the movement of both molecules into the mitochondrion and facilitating percutaneous absorption, in which both the melatonin and the CoQ10 can reach all of the strata of the skin.

Abstract: Described herein is a method for treating hair including: (a) putting the hair in a desired shape; (b) before and/or after the hair is put in the desired shape, applying a reducing composition to the hair including: (i) from about 2.5% to about 15% of a cationic mercapto amino pyridinium compound or a cationic dimercapto amino pyridinium compound; (ii) from about 4% to about 10% of a buffering system; and (iii) from about 50% to about 93.5% of a solvent; (c) rinsing the reducing composition from the hair; (d) applying an oxidizing composition to the hair including: (i) from about 0.5% to about 12% of an oxidizing agent; and (ii) from about 80% to about 97% of a solvent; and (e) rinsing the oxidizing composition from the hair. The reducing composition has a pH of from about 8 to about 10.

Abstract: A hair care composition comprising from about 10% to about 25% of one or more surfactants; from about 0.01% to 10% of one or more surfactant soluble antidandruff agents; from about 0.1% to 10% of one or more anionic polymers from about 0.01% to 5% of one or more cationic polymers; wherein the composition has a deposition efficiency of greater than 1.2X that of a control composition wherein the control composition comprises 14% SLE1S, no polymeric constituents, 1% of the surfactant soluble antidandruff agent at a pH of about 6.

Abstract: A hair care composition comprising from about 10% to about 25% of one or more surfactants; from about 0.01% to 10% of one or more surfactant soluble antidandruff agents; from about 0.5% to 10% of one or more thickening polymers that are able to raise the viscosity of the formulation to at least 3000 cps at 2 s?1; wherein the composition without thickening polymer has a viscosity of less than about 3000 cps at 2 s?1 and is unable to be thickened above 3000 cps at 2 s?1 with sodium chloride salt in the range of about 0.1% to about 3%.

Abstract: Described herein is a lotion composition including a soil capture polymer, the soil capture polymer having a number average molecular weight of at least 1,000,000 and a cationic charge of at least 1 meq/g, and the lotion pH being from about 3.5 to about 5.5. The lotion composition may be incorporated along with a substrate into a wet wipe.

Abstract: The instant disclosure relates to anhydrous hair-treatment compositions. The anhydrous hair-treatment compositions typically include one or more bis-urea derivatives, hydrophobic silica aerogel, and one or more solvents, for example, ester oils and non-ester oil solvents. Additional components such as silicones, etc., can also be included. Kits comprising the hair-treatment compositions and methods of using the hair-treatment compositions are also disclosed.

Abstract: The instant disclosure relates to hair-treatment compositions. The hair-treatment compositions typically include: one or more polyurethane latex polymers; one or more cationic emulsifiers and/or surfactants; one or more fatty compounds; and water. Additional components such as water-soluble solvents, silicones, cationic polymers, etc., can also be included. The instant disclosure also relates to kits that include the hair-treatment compositions and to methods for treating hair with the hair-treatment compositions.

Abstract: The instant disclosure relates to hair-treatment compositions. The hair-treatment compositions typically include: one or more polyurethane latex polymers; one or more thickening agents; one or more water-soluble solvents; and water. Additional components such as silicones, emulsifiers, surfactants, cationic polymers, etc., can also be included. The instant disclosure also relates to kits that include the hair-treatment compositions and to methods for treating hair with the hair-treatment compositions.

Abstract: The present invention relates to a fluid anhydrous composition comprising, especially in a cosmetically acceptable medium: a) at least 20% of a silicone fatty phase, and b) at least 5% of one or more lipophilic organic UV screening agents, and c) at least one or more C2-C8 monoalcohols. The present invention also relates to the use of said composition for the manufacture of products for the cosmetic treatment of the skin, the nails, the hair, the eyelashes, eyebrows and/or the scalp, especially care products, anti-sun products, makeup products and perfuming products.

Abstract: A composition for treating skin pigmentation, a method of forming the composition, and a method of treating skin pigmentation are disclosed. The composition comprises at least one pharmaceutically acceptable additive. The composition further comprises at least one melanin production inhibitor, which may be a depigmentation agent. The melanin production inhibitor is present in an amount effective to inhibit melanin production in human skin cells of a subject that is administered the composition.

Abstract: The present invention provides a skin penetration enhancing method and its penetration enhancer which is comprised of sponge spicules or a biologically effective amount of sponge spicules or a combination containing sponge spicules. The penetration enhancer can be applied onto the skin to overcome the skin stratum corneum barrier, which can increase the percutaneous absorption of drugs, vaccines and cosmetics into different skin layers or can improve the transdermal delivery of all these therapeutics into the systemic blood circulation. This technology can be used for dermal delivery of therapeutics into the skin or for transdermal delivery of therapeutics across the skin into systemic blood circulation.

Abstract: The present invention relates to a probiotic cosmetic formulation for the cosmetic treatment of the skin, comprising a microbiota and a cosmetically acceptable carrier. Preferably, betaines and/or prebiotic agents may be incorporated into said formulation. The invention also relates to the use of a microbiota in preparing said probiotic cosmetic formulation of the invention, and a method for the cosmetic treatment of the skin, which comprises administering to the skin of an individual the probiotic cosmetic formulation of the invention.

Abstract: A skin care composition for stimulating selective catabolysis in cells of keratin surfaces comprising at least one autophagy activator and at least one proteasome activator, and a method for improving selective catabolysis in cells of keratin surfaces by treating with the composition.

Abstract: The present disclosure relates to self-emulsifying pharmaceutical compositions for transmucosal delivery of biologically active peptides and proteins.

Abstract: Mono- or multilayered, film-shaped, pressure-sensitive adhesive preparations for application in the oral region and a process for manufacturing such preparations. The preparations contain at least one poly-methylvinylether-maleic acid anhydride copolymer, polyvinyl acetate and/or at least one copolymer of the polyvinyl acetate with vinyl alcohol esters of fatty acids, as well as at least one cosmetic and/or pharmaceutical active substance.

Abstract: The present invention relates to compositions comprising a colloidal dispersion and an Agent of Interest (“AOI”), wherein the colloidal dispersion comprises deformable colloidal particles and wherein the AOI is not associated with the deformable colloidal particles. The present invention also provides kits and transdermal drug release devices comprising the compositions of the present invention, and the use of these compositions in medicine, skin care and cosmetics.

Abstract: A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.

Abstract: This invention relates to a depot formulation comprising a biodegradable silica hydrogel composite incorporating a nucleotide or nucleoside analogue reverse transcriptase inhibitor, wherein the silica hydrogel composite is obtainable by mixing silica particles comprising said nucleotide or nucleoside analogue reverse transcriptase inhibitor and having a maximum diameter of ?1 000 ?m, as such or as a suspension, with silica sol wherein the hydrogel composite is non-flowing and structurally stable when stored at rest and shear-thinning when shear stress is applied by injection. The present invention also relates to use of the depot formulation for treatment of chronic viral infections and prevention of chronic viral reinfection. The present invention further relates to a prefilled syringes comprising said depot formulation.

Abstract: The present invention relates to an expandable plug body for use in a vagina which is expandable at a predetermined value in an aqueous solution and has an expansion value of 1 to 30 at saturated water absorption. Effective components may be immersed in the interior of the expandable plug body, or dissolved and dispersed in the material wrapping the expandable plug body. The expandable plug body is primarily used in the vagina. The present invention provides an expandable plug body having some unique physical properties such as expanding at a predetermined expansion value, expanding at a specific pH value, and periodically expanding, so that it has a good performance when used as a medicine, a cosmetic, and a disinfection product. After the application of the original liquid of the expandable plug body onto the vagina for 3˜5 min, antibacterial rates of which on E. coli, Staphylococcus aureus and Candida albicans are all in the range of 89˜95%.

Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.

Abstract: Disclosed herein are methods for treating an individual diagnosed with ABC-DLBCL. The methods include administering to the individual an inhibitor of Bruton's tyrosine kinase (Btk).

Abstract: Gastric residence systems comprising therapeutic agent formulations for sustained gastric release of therapeutic agents are disclosed, as well as methods for using such systems. The systems are characterized by use of a dispersant in the formulations, which improves the burst release characteristics and long-term release rate characteristics of the systems. Milling of therapeutic agent can also be performed to prepare agent particles of desired size.

Abstract: The present invention relates to an oral enteric high-dose tablet comprising mesalazine as the active substance as well as its use.